| Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis (NCT05706220) | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | 2022-06-13 |
| A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) (NCT05123703) | Hoffmann-La Roche | 2022-05-19 |
| A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation (NCT05090371) | Novartis Pharmaceuticals | 2022-03-02 |
| Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS (NCT05604092) | Assiut University | 2022-03-01 |
| Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE (NCT05446285) | NHS Greater Glasgow and Clyde | 2022-02-07 |
| Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment (NCT05171972) | University of Southern California | 2022-01-29 |
| Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis (NCT05351411) | Firat University | 2021-11-01 |
| Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies (NCT06586177) | Heinrich-Heine University, Duesseldorf | 2021-10-27 |
| Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial (NCT04971005) | Universitätsklinikum Hamburg-Eppendorf | 2021-08-27 |
| MS Relapses During COVID-19 Pandemic (NCT04858763) | Nottingham University Hospitals NHS Trust | 2021-07-01 |
| Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate (NCT04925778) | Banner Life Sciences LLC | 2021-06-30 |
| Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (NCT04940065) | Novartis Pharmaceuticals | 2021-06-30 |
| Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects (NCT05181215) | Banner Life Sciences LLC | 2021-05-14 |
| Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis (NCT04688788) | Rigshospitalet, Denmark | 2021-04-28 |
| Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (NCT06663111) | Haukeland University Hospital | 2021-03-15 |
| A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis (NCT04711148) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-03-01 |
| Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region (NCT04468165) | Hikma Pharmaceuticals LLC | 2021-02-23 |
| Investigation of Subclinical Markers of Multiple Sclerosis (NCT04604041) | University of Split, School of Medicine | 2020-11-23 |
| Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (NCT04602390) | Anokion SA | 2020-11-06 |
| Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease (NCT04578639) | Haukeland University Hospital | 2020-11-02 |
| SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis (NCT03783416) | Queen Mary University of London | 2020-06-15 |
| Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis (NCT04009005) | Terry L. Wahls | 2020-05-01 |
| Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis (NCT04225312) | Amsterdam UMC, location VUmc | 2020-02-03 |
| Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis (NCT04530318) | Judit Pich | 2020-01-27 |
| Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis (NCT04201470) | University Hospital, Montpellier | 2019-12-09 |
| Study of Evobrutinib in Participants With RMS (NCT04032171) | EMD Serono Research & Development Institute, Inc. | 2019-09-10 |
| Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) (NCT04032158) | EMD Serono Research & Development Institute, Inc. | 2019-08-26 |
| PET with [18F]Flumazenil As an Index of Neurodegeneration in MS (NCT03825601) | Institut National de la Santé Et de la Recherche Médicale, France | 2019-05-02 |
| Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis (NCT03536559) | Clene Nanomedicine | 2018-11-23 |
| Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS (NCT03718247) | University of Virginia | 2018-10-31 |
| Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus (NCT03562975) | University of South Florida | 2018-07-23 |
| Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients (NCT04115930) | University of Eastern Finland | 2018-05-16 |
| Melatonin in Patients With Multiple Sclerosis (MS). (NCT03498131) | Providence Health & Services | 2018-05-09 |
| Mechanistic Studies of Teriflunomide in RRMS (NCT03464448) | University of Michigan | 2018-04-17 |
| Intermittent Fasting in Multiple Sclerosis (NCT03539094) | Washington University School of Medicine | 2018-01-01 |
| Behavior and Activity Monitoring in MS (NCT03244696) | Ohio State University | 2017-11-02 |
| Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme (NCT03471338) | University Hospital, Caen | 2017-10-31 |
| Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes (NCT03284970) | EMD Serono Research & Development Institute, Inc. | 2017-08-23 |
| COMparison Between All immunoTherapies for Multiple Sclerosis. (NCT03193866) | Karolinska Institutet | 2017-06-02 |
| An Extension of the TG1101-RMS201 Trial (NCT03381170) | TG Therapeutics, Inc. | 2017-06-01 |
| Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab (NCT03157830) | Providence Health & Services | 2017-06-01 |
| Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis (NCT03302442) | Nantes University Hospital | 2017-05-01 |
| Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis (NCT03345940) | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 2017-04-30 |
| A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 (NCT03093324) | Biogen | 2017-03-15 |
| Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy (NCT03091569) | Biogen | 2017-03-10 |
| A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis (NCT02975349) | EMD Serono Research & Development Institute, Inc. | 2017-03-07 |
| Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (NCT03177083) | Biogen | 2017-01-30 |
| Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects (NCT04570670) | Banner Life Sciences LLC | 2017-01-06 |
| Clinical Importance of Glucose Regulation in Relapsing MS (NCT03004079) | University of Virginia | 2016-10-01 |
| Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) (NCT02720107) | Novartis Pharmaceuticals | 2016-05-12 |
| Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (NCT02428218) | Biogen | 2016-05-01 |
| Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® (NCT02823951) | IMS HEALTH GmbH & Co. OHG | 2016-02-01 |
| Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis. (NCT02833714) | University of North Carolina, Chapel Hill | 2016-01-01 |
| Clinical Disease Activity With Long Term Natalizumab Treatment (NCT02677077) | Biogen | 2015-12-31 |
| A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis (NCT02647502) | Johns Hopkins University | 2015-12-01 |
| Teriflunomide Observational Effectiveness Study (NCT02490982) | Centre hospitalier de l'Université de Montréal (CHUM) | 2015-11-01 |
| Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis (NCT03000647) | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 2015-10-01 |
| Mitochondrial Dysfunction and Disease Progression (NCT02549703) | Icahn School of Medicine at Mount Sinai | 2015-09-01 |
| Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis (NCT02472938) | Biogen | 2015-07-01 |
| High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients (NCT02696590) | Isfahan University of Medical Sciences | 2015-07-01 |
| Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate (NCT02090348) | Biogen | 2015-06-01 |
| Autologous Mesenchymal Stromal Cells for Multiple Sclerosis (NCT02495766) | Banc de Sang i Teixits | 2015-05-11 |
| Fingolimod Effect on Cytokine and Chemokine Levels (NCT02373098) | Novartis Pharmaceuticals | 2015-03-31 |
| Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 (NCT02306811) | Genzyme, a Sanofi Company | 2015-02-01 |
| Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (NCT02255656) | Genzyme, a Sanofi Company | 2015-01-07 |
| Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (NCT02364986) | PD Dr. Marcus Müller | 2015-01-01 |
| Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (NCT02342704) | Biogen | 2014-11-30 |
| PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod (NCT02335892) | Novartis Pharmaceuticals | 2014-11-11 |
| Comparative Oral Bioavailability Study of MT-1303 (NCT02310048) | Tanabe Pharma Corporation | 2014-11-01 |
| Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis (NCT02266121) | University Hospital of Mont-Godinne | 2014-10-01 |
| Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (NCT02205489) | Genzyme, a Sanofi Company | 2014-10-01 |
| Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (NCT02222948) | Genzyme, a Sanofi Company | 2014-09-01 |
| Mass Balance Study of MT-1303 (NCT02293967) | Tanabe Pharma Corporation | 2014-09-01 |
| Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (NCT02283853) | Biogen | 2014-08-28 |
| Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) (NCT02159573) | Biogen | 2014-07-01 |
| Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation (NCT02217982) | Rocky Mountain MS Research Group, LLC | 2014-07-01 |
| Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (NCT02125604) | Biogen | 2014-06-01 |
| Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) (NCT02258217) | OhioHealth | 2014-06-01 |
| Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (NCT02090413) | Biogen | 2014-05-01 |
| Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya (NCT02325440) | University Hospital Muenster | 2014-03-01 |
| Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis (NCT02104492) | University of Malaga | 2014-03-01 |
| A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (NCT01975298) | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-01-01 |
| Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS (NCT02010554) | University of Missouri, Kansas City | 2013-12-01 |
| Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (NCT04832399) | Biogen | 2013-11-12 |
| A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (NCT01930708) | Biogen | 2013-10-31 |
| Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis (NCT02753088) | Biocad | 2013-10-01 |
| Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) (NCT01963611) | EMD Serono | 2013-10-01 |
| Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod (NCT01790269) | Charite University, Berlin, Germany | 2013-09-01 |
| Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design (NCT01945359) | Rocky Mountain MS Research Group, LLC | 2013-09-01 |
| A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (NCT01917019) | Biogen | 2013-08-01 |
| Extension Study of MT-1303 (NCT01890655) | Tanabe Pharma Corporation | 2013-08-01 |
| Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (NCT01709812) | Novartis Pharmaceuticals | 2013-07-01 |
| PK and PD Study of Natalizumab in Pediatric Subjects With RRMS (NCT01884935) | Biogen | 2013-07-01 |
| Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (NCT02076841) | Biogen | 2013-07-01 |
| Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (NCT01717664) | RedHill Biopharma Limited | 2013-06-01 |
| Safety and Tolerability of Glatiramer Acetate (NCT01874145) | Teva Branded Pharmaceutical Products R&D, Inc. | 2013-06-01 |
| Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. (NCT01808885) | Hoffmann-La Roche | 2013-04-01 |
| Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (NCT01767701) | Queen Mary University of London | 2013-04-01 |
| Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality (NCT01805336) | University Hospital, Caen | 2013-03-28 |
| An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (NCT01838668) | Biogen | 2013-03-28 |